Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases (IBCSG 23-01): A phase 3 randomised controlled trial

The Lancet Oncology

Volumn 14, Issue 4, 2013, Pages 297-305

  Galimberti, Viviana ^a   Cole, Bernard F ^b,c   Zurrida, Stefano ^a   Viale, Giuseppe ^a,d   Luini, Alberto ^a   Veronesi, Paolo ^a,d   Baratella, Paola ^a   Chifu, Camelia ^a   Sargenti, Manuela ^a   Intra, Mattia ^a   Gentilini, Oreste ^a   Mastropasqua, Mauro G ^a   Mazzarol, Giovanni ^a   Massarut, Samuele ^e   Garbay, Jean Rémi ^f   Zgajnar, Janez ^g   Galatius, Hanne ^h   Recalcati, Angelo ⁱ   Littlejohn, David ^j   Bamert, Monika ^k   Colleoni, Marco ^a   Price, Karen N ^c,l   Regan, Meredith M ^c,m   Goldhirsch, Aron ^a   Coates, Alan S ⁿ   Gelber, Richard D ^c,l,m,o   Veronesi, Umberto ^a   more..

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^b University of Vermont   (United States)

^c DANA FARBER CANCER INSTITUTE   (United States)

^d UNIVERSITY OF MILAN   (Italy)

^e CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

^f INSTITUT GUSTAVE ROUSSY   (France)

^g INSTITUTE OF ONCOLOGY   (Slovenia)

^h GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

ⁱ A MANZONI HOSPITAL   (Italy)

^j Riverina Cancer Care Centre   (Australia)

^k Breast Center Kantonsspital   (Switzerland)

^l FRONTIER SCIENCE AND TECHNOLOGY RESEARCH FOUNDATION   (United States)

^m HARVARD MEDICAL SCHOOL   (United States)

ⁿ UNIVERSITY OF SYDNEY   (Australia)

^o HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; AXILLARY LYMPH NODE EXTIRPATION; BREAST CANCER; CANCER RECURRENCE; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; LYMPH NODE DISSECTION; LYMPHEDEMA; MAJOR CLINICAL STUDY; MENOPAUSE; MICROMETASTASIS; MOTOR NEUROPATHY; MULTICENTER STUDY; OUTCOME ASSESSMENT; PHASE 3 CLINICAL TRIAL; POSTOPERATIVE INFECTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SENSORY NEUROPATHY; SENTINEL LYMPH NODE BIOPSY; SENTINEL LYMPH NODE METASTASIS; SURVIVAL TIME; TUMOR VOLUME;

ADULT; AGED; AXILLA; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; LYMPH NODES; LYMPHATIC METASTASIS; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM MICROMETASTASIS; SENTINEL LYMPH NODE BIOPSY; TREATMENT OUTCOME;

EID: 84875804030     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(13)70035-4     Document Type: Article

References (29)

1. Veronesi U, Paganelli G, Viale G, et al. A randomized comparison of sentinel-node biopsy with routine axillary dissection in breast cancer. N Engl J Med 2003, 349:546-553.
2. Krag D, Weaver D, Ashikaga T, et al. The sentinel node in breast cancer-a multicenter validation study. N Engl J Med 1998, 339:941-946.
3. Straver ME, Meijnen P, van Tienhoven G, et al. Sentinel node identification rate and nodal involvement in the EORTC 10981-22023 AMAROS trial. Ann Surg Oncol 2010, 17:1854-1861.
4. Veronesi U, Viale G, Paganelli G, et al. Sentinel lymph node biopsy in breast cancer: ten-year results of a randomized controlled study. Ann Surg 2010, 251:595-600.
5. Lyman GH, Giuliano AE, Somerfield MR, et al. American Society of Clinical Oncology guideline recommendations for sentinel lymph node biopsy in early-stage breast cancer. J Clin Oncol 2005, 23:7703-7720. and the American Society of Clinical Oncology.
6. Giuliano AE, Hunt KK, Ballman KV, et al. Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial. JAMA 2011, 305:569-575.
7. Veronesi U, Galimberti V, Paganelli G, et al. Axillary metastases in breast cancer patients with negative sentinel nodes: a follow-up of 3548 cases. Eur J Cancer 2009, 45:1381-1388.
8. Naik AM, Fey J, Gemignani M, et al. The risk of axillary relapse after sentinel lymph node biopsy for breast cancer is comparable with that of axillary lymph node dissection: a follow-up study of 4008 procedures. Ann Surg 2004, 240:462-468.
9. Smidt ML, Janssen CM, Kuster DM, Bruggink ED, Strobbe LJ Axillary recurrence after a negative sentinel node biopsy for breast cancer: incidence and clinical significance. Ann Surg Oncol 2005, 12:29-33.
10. Siponen ET, Vaalavirta LA, Joensuu H, Leidenius MH Axillary and supraclavicular recurrences are rare after axillary lymph node dissection in breast cancer. World J Surg 2012, 36:295-302.
11. Van Zee KJ, Manasseh DME, Bevilacqua JLB, et al. A nomogram for predicting the likelihood of additional nodal metastases in breast cancer patients with a positive sentinel node biopsy. Ann Surg Oncol 2003, 10:1140-1151.
12. Mansel RE, Goyal A European studies on breast lymphatic mapping. Semin Oncol 2004, 31:304-310.
13. Olson JA, McCall LM, Beitsch P, et al. Impact of immediate versus delayed axillary node dissection on surgical outcomes in breast cancer patients with positive sentinel nodes: results from American College of Surgeons Oncology Group Trials Z0010 and Z0011. J Clin Oncol 2008, 26:3530-3535. the American College of Surgeons Oncology Group Trials Z0010 and Z0011.
14. Lucci A, McCall LM, Beitsch PD, et al. Surgical complications associated with sentinel lymph node dissection (SLND) plus axillary lymph node dissection compared with SLND alone in the American College of Surgeons Oncology Group Trial Z0011. J Clin Oncol 2007, 25:3657-3663. the American College of Surgeons Oncology Group.
15. Viale G, Maiorano E, Mazzarol G, et al. Histologic detection and clinical implications of micrometastases in axillary sentinel lymph nodes for patients with breast carcinoma. Cancer 2001, 92:1378-1384.
16. American Joint Committee on Cancer: AJCC cancer staging manual 2002, 157-164. Springer, New York. 6th edn. F.L. Greene, D.L. Page, I.D. Fleming (Eds.).
17. AJCC cancer staging manual 2010, 143-164. Springer, New York. 7th ed. S.B. Edge, D.R. Byrd, C.C. Compton, A.G. Fritz, F.L. Greene, A. Trotti (Eds.).
18. Effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer. An overview of 61 randomized trials among 28,896 women. Early Breast Cancer Trialists' Collaborative Group. N Engl J Med 1988, 319:1681-1692. EBCTCG (Early Breast Cancer Trialists' Collaborative Group).
19. Gray RJ A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 1988, 16:1141-1154.
20. Veronesi U, Orecchia R, Luini A, et al. Full-dose intraoperative radiotherapy with electrons during breast-conserving surgery: experience with 590 cases. Ann Surg 2005, 242:101-106.
21. Giuliano AE, McCall L, Beitsch P, et al. Locoregional recurrence after sentinel lymph node dissection with or without axillary dissection in patients with sentinel lymph node metastases: the American College of Surgeons Oncology Group Z0011 randomized trial. Ann Surg 2010, 252:426-432.
22. Wasif N, Maggard MA, Ko CY, Giuliano AE Underuse of axillary dissection for the management of sentinel node micrometastases in breast cancer. Arch Surg 2010, 145:161-166.
23. Straver ME, Meijnen P, van Tienhoven G, et al. Role of axillary clearance after a tumor-positive sentinel node in the administration of adjuvant therapy in early breast cancer. J Clin Oncol 2010, 28:731-737.
24. The EORTC. 10981-22023 AMAROS trial website:. http://research.nki.nl/amaros/.
25. Colleoni M, Rotmensz N, Peruzzotti G, et al. Size of breast cancer metastases in axillary lymph nodes: clinical relevance of minimal lymph node involvement. J Clin Oncol 2005, 23:1379-1389.
26. Goldhirsch A, Glick JH, Gelber RD, Senn HJ Meeting highlights: International Consensus Panel on the Treatment of Primary Breast Cancer. J Natl Cancer Inst 1998, 90:1601-1608.
27. Goldhirsch A, Ingle JN, Gelber RD, Coates AS, Thürlimann B, Senn HJ Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009. Ann Oncol 2009, 20:1319-1329. the Panel members.
28. Goldhirsch A, Wood WC, Gelber RD, Coates AS, Thürlimann B, Senn HJ Meeting highlights: updated international expert consensus on the primary therapy of early breast cancer. J Clin Oncol 2003, 21:3357-3365.
29. Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thürlimann B, Senn HJ Panel members. Strategies for subtypes-dealing with the diversity of breast cancer: highlights of the St. Gallen International expert consensus on the primary therapy of early breast cancer 2011. Ann Oncol 2011, 22:1736-1747. the Panel members.